Table 1 Clinical and instrumental characteristic of study population
Asymptomatic SARS-COV-2 Positive patients (N= 46) | SARS-COV-2 Negative patients (N = 130) | P | |
|---|---|---|---|
Age, years | 56.13 ± 6.21 | 68.43 ± 6.46 | 0.006 |
Male, n (%) | 31 (67.4) | 86 (66.2) | 0.515 |
BMI (kg/m2) | 27.09 ± 1.81 | 29.55 ± 1.97 | 0.003 |
Diabetes, n (%) | 8 (17.4) | 38 (29.2) | 0.478 |
Dyslipidemia, n (%) | 7 (15.2) | 30 (23.7) | 0.181 |
Hypertension, n (%) | 18 (39.1) | 72 (55.4) | 0.042 |
Smoking, n (%) | 3 (6.5) | 39 (29.2) | 0.001 |
Acetylsalicylic acid, n (%) | 21 (45.6) | 60 (46.1) | 0.546 |
Ace-inhibitors, n (%) | 15 (32.6) | 45 (34.6) | 0.477 |
AT II receptor blocker | 6 (13.1) | 25 (19.2) | 0.239 |
Insulin, n (%) | 2 (4.3) | 5 (3.8) | 0.587 |
Oral anti-diabetic drugs, n (%) | 6 (13.1) | 30 (23.1) | 0.106 |
Statin, n (%) | 7 (15.2) | 27 (20.8) | 0.278 |
Glycemia (mg/dl) | 129.65 ± 21.02 | 129.22 ± 27.64 | 0.924 |
Cholesterol (mg/dl) | 181.2 ± 21.4 | 197.7 ± 21.1 | 0.001 |
LDL-cholesterol (mg/dl) | 111.57 ± 21.65 | 123.83 ± 20.43 | 0.010 |
Triglycerides (mg/dl) | 163.91 ± 23.63 | 181.79 ± 18.06 | 0.001 |
LDH (unit/l) | 367.83 ± 37.41 | 375.46 ± 33.32 | 0.126 |
Creatinine (mg/dl) | 0.92 ± 0.22 | 1.04 ± 0.14 | 0.001 |
Fibrinogen (g/l) | 3.68 ± 0.37 | 3.75 ± 0.33 | 0.198 |
White cells count (109/l) | 15.76 ± 1.27 | 12.49 ± 4.82 | 0.002 |
Lymphocyte (109/l) | 1.76 ± 0.20 | 1.80 ± 0.14 | 0.130 |
Virus load CT, n | 26.02 ± 2.22 | / | / |
Thrombus virus load CT, n | 25.46 ± 8.68 | / | / |
Ejection fraction (%) | 41.49 ± 1.82 | 47.25 ± 3.55 | 0.003 |
LAD, n (%) | 31 (67.4) | 74 (56.9) | 0.091 |
LMS, n (%) | 8 (17.4) | 15 (11.3) | 0.145 |
Cx, n (%) | 5 (10.9) | 13 (10.0) | 0.520 |
RCA, n (%) | 12 (26.1) | 39 (30.0) | 0.349 |
GP IIb/IIIa inhibitor, n (%) | 25 (54.3) | 19 (14.6) | 0.006 |
Multi-vessel PCI, n (%) | 10 (21.7) | 11 (8.5) | 0.020 |
Thrombus dimension, mm2 | 4.21 ± 1.12 | 2.71 ± 0.42 | 0.001 |
Modified thrombus G 5, n (%) | 41 (89.1) | 30 (23.1) | 0.001 |
Multivessel thrombus, n (%) | 16 (34.8) | 12 (9.2) | 0.001 |
Post-PPCI TIMI 3, n (%) | 43 (93.5) | 124 (95.4) | 0.432 |
Blush grade 2–3, n (%) | 12 (26.1) | 127 (97.7) | 0.001 |
Total heparin dose, U | 12777.78 ± 356 | 10137.55 ± 299 | 0.047 |
Door-to-balloon time (min) | 54 (38–72) | 51 (35.3–57.9) | 0.345 |
Average ACT | 268.7 ± 67.2 | 271.6 ± 59.3 | 0.167 |
MACE | |||
Death, n (%) | 4 (8.7) | 2 (1.5) | 0.041 |
Non-fatal AMI, n (%) | 6 (13.0) | 4 (3.1) | 0.021 |
Heart failure, n (%) | 4 (8.7) | 3 (2.3) | 0.077 |